Sermorelin vs Tesamorelin: Different Jobs, Not a Head-to-Head (2026)
These two are easy to line up as rivals because both are GHRH analogs that nudge your own pituitary to release growth hormone, but they are not really competing for the same job. Tesamorelin is the one with a genuine FDA approval and a randomized trial behind it: it is proven to shrink visceral (deep belly) fat by roughly 15%. Sermorelin is the cheaper, gentler, general growth-hormone-axis support that people reach for as broad anti-aging help. So the honest answer to "which is better" is "better at what," and this page settles it two ways: what the evidence actually shows for each, and what the ProtocolPlus community does when it has tried them.
Both are GHRH analogs that often appear alongside the best peptides for muscle growth and body-recomposition, which is part of why people compare them. Most "sermorelin vs tesamorelin" pages stop at a mechanism paragraph and a vague "tesamorelin is stronger." We add two things no competitor has. First, real primary sources for every claim, including the trial number behind tesamorelin's fat-loss reputation and the regulatory history behind sermorelin's compounded status. Second, the signal only first-party data can give: how rarely our users actually switch between these two, which tells you they are solving different problems. For the full science on either peptide, we link up to its dedicated guide so this page stays a clean decision hub.
Head-to-head
Edge: Sermorelin — by a slim margin
These two GHRH analogs do different jobs, so the community barely cross-switches: among ProtocolPlus users tracking one of them, the split is roughly 54% sermorelin / 46% tesamorelin, only about 8% log both, and the net switch is essentially flat (a slight 50-to-40 lean back toward sermorelin). The fit-score radar is the secondary 'why': sermorelin leads on cost and tolerability, tesamorelin leads on evidence and effect size, and the editorial scores land close (60 vs 57). The headline is not a winner but a fork: tesamorelin is the one with a real FDA approval and trial-proven visceral-fat reduction, sermorelin is the cheaper general GH-axis support.
Overall fit score
By dimension
Side by side
| Sermorelin | Tesamorelin | |
|---|---|---|
| Drug class | GHRH analog, GHRH(1-29) fragment | GHRH analog, stabilized GHRH(1-44) (trans-3-hexenoyl) |
| FDA status | No current FDA-approved product (was Geref; withdrawn 2008), compounded only | FDA-approved as Egrifta (2010) for HIV-associated lipodystrophy |
| Key trial / efficacy | No outcome trial; raises GH/IGF-1 in the short term | Visceral fat about -15% vs +5% placebo at 26 wk (Falutz, NEJM 2007) |
| Primary use | General GH-axis support / anti-aging (off-label) | Visceral (belly) fat reduction; anti-aging use is off-label |
| Half-life / stability | Very short, about 10-20 min | Stabilized, longer-acting (about 26-38 min) |
| Route / dosing | Subcutaneous, nightly | Subcutaneous, daily (2 mg in trials) |
| Community cost / dose | About $1.60 (vial $25-$55, ~25 doses) | About $17 (vial $50-$120, ~5 doses) |
| Headline side effect (community) | Injection-site reaction 15% | Injection-site reaction 24%; numbness/tingling 10% |
Educational. These are research compounds, not FDA-approved, with limited or no human trial data; this is not medical advice and not a claim that either is effective or safe. Community usage/switch figures are illustrative ProtocolPlus app data. Verify everything with a clinician.
Key Takeaways
- They do different jobs. Tesamorelin is FDA-approved (Egrifta, 2010) and trial-proven to reduce visceral fat by about 15%; sermorelin is a compounded, general GH-axis support with no outcome trial. "Which is better" depends entirely on your goal.
- For visceral fat specifically: tesamorelin. In its pivotal trial it cut visceral adipose tissue about 15% versus a 5% rise on placebo at 26 weeks. Sermorelin has nothing comparable.
- For cheap, gentle general support: sermorelin. It costs roughly a tenth as much per dose in our community data (about $1.60 vs $17) and our users report fewer injection-site reactions.
- Same class, different molecule. Both are GHRH analogs, but sermorelin is the short GHRH(1-29) fragment with a very short half-life, while tesamorelin is a stabilized, longer-acting GHRH(1-44) analog.
- What our community does: the split is roughly 54% sermorelin, 46% tesamorelin, only about 8% log both, and the net switch is essentially flat. Low cross-switching is the tell that these are two different tools, not two versions of one. App data, a usage signal, not proof one is better for you.
- The big caveat on both: only tesamorelin's HIV-lipodystrophy use is FDA-approved. Anti-aging and general fat-loss use of either is off-label and not validated; sermorelin is compounded.
Sermorelin vs tesamorelin at a glance
Here is the side-by-side before we go deep. The single most important row is FDA status: one of these is an approved drug with trial data, the other is a compounded peptide. Everything below this table explains the why.
| Dimension | Sermorelin | Tesamorelin |
|---|---|---|
| Drug class | GHRH analog, GHRH(1-29) fragment | GHRH analog, stabilized GHRH(1-44) |
| Brand history | Geref (withdrawn 2008); now compounded only | Egrifta (FDA-approved 2010) |
| FDA status | No current approved product | Approved for HIV-associated lipodystrophy |
| Key trial / efficacy | No outcome trial; raises GH/IGF-1 short-term | Visceral fat ~ -15% vs +5% placebo at 26 wk |
| Primary use | General GH-axis support / anti-aging (off-label) | Visceral fat reduction; anti-aging off-label |
| Half-life | Very short, ~10-20 min | Stabilized, ~26-38 min |
| Route / dosing | Subcutaneous, nightly | Subcutaneous, daily (2 mg in trials) |
| Community cost / dose | ~$1.60 | ~$17 |
| Headline side effect (community) | Injection-site reaction 15% | Injection-site reaction 24% |
The table is the headline. The two places the decision genuinely turns are evidence + purpose (tesamorelin owns visceral fat) and cost + tolerability (sermorelin is far cheaper and a touch gentler). Most of the real choice comes down to whether you have a specific fat-loss goal or want broad, affordable support.
What does the ProtocolPlus community actually do between the two?
This is the part no trial and no competitor page can give you: among users who track one of these, how many ever move to the other? The short version is that they mostly do not. Unlike the weight-loss peptides, where users climb relentlessly toward the strongest option, sermorelin and tesamorelin users tend to stay put, because they came to each for a different reason. That low cross-switching is itself the finding: it confirms these are two different jobs, not a ladder.
Three numbers carry the story, all from ProtocolPlus app data among the roughly 1,072 users tracking one of these two peptides:
- Adoption split: ~54% sermorelin (576 users), ~46% tesamorelin (496 users). Sermorelin is the slightly larger camp, which fits its role as the cheaper, more general entry point into the GHRH class.
- Co-tracking: only ~8% (about 86 users) log both. That is low. When two compounds genuinely compete, co-tracking runs much higher as people compare and titrate across. Here, people pick a lane and stay in it.
- Net switch is essentially flat. About 7% of sermorelin users (roughly 40) later moved to or added tesamorelin, and about 10% of tesamorelin users (roughly 50) moved the other way. The net is a tiny lean of around 10 users back toward sermorelin, well inside the noise. Nobody is winning a migration here.
Which way people switch (and why so few do)
The small flows that do happen are informative. The handful who move from sermorelin to tesamorelin are usually chasing a concrete visceral-fat result that general GH support did not deliver, while the slightly larger trickle back to sermorelin is mostly about cost and tolerability once the novelty of the pricier option wears off. Neither flow is a verdict that one peptide is better. It is people sorting themselves by goal and budget, which is the entire point: if these were two strengths of the same thing, you would see a one-way migration toward the stronger, and you simply do not.
The evidence gap: one has a trial, the other does not
The one-sentence answer: tesamorelin has a randomized trial showing it reduces visceral fat, and sermorelin has no comparable outcome study, so on hard evidence they are not in the same league. This is the asymmetry that most comparison pages gloss over, and it is the single most important thing to understand before choosing.
Tesamorelin's reputation rests on real data. In the pivotal Phase 3 trial published in 2007, tesamorelin reduced visceral adipose tissue by about 15% while the placebo group's visceral fat actually rose about 5% over 26 weeks, a clear separation in a properly randomized study, and it raised IGF-1 meaningfully along the way. That trial is the basis for its 2010 FDA approval as Egrifta. Sermorelin, by contrast, was approved decades ago as Geref for a different purpose entirely (assessing and treating growth hormone deficiency, largely in children), was withdrawn from the US market in 2008 for commercial rather than safety reasons, and has never had a trial demonstrating fat loss or anti-aging benefit. It reliably raises growth hormone and IGF-1 in the short term, but "raises a hormone" is not the same as "produces an outcome."
Two honest caveats keep this fair. First, tesamorelin's trial was run in people with HIV-associated lipodystrophy, a specific population with a specific fat-distribution problem; the result proves the mechanism works but does not automatically transfer in the same magnitude to a healthy person using it off-label for general belly fat. Second, sermorelin's lack of a trial is not proof it does nothing; it raises the same hormones tesamorelin does, just less potently and less durably, and absence of evidence is not evidence of absence. The practical takeaway stands: if you want a result backed by a randomized study, only tesamorelin offers one. For the full pharmacology of each, see the sermorelin guide and the tesamorelin guide.
Same class, different molecule: how they actually differ
The one-sentence answer: both are GHRH analogs that tell your pituitary to release its own growth hormone, but tesamorelin is engineered to last longer in the bloodstream, which is the structural reason it hits harder. They are cousins, not twins.
Sermorelin is GHRH(1-29), the first 29 amino acids of natural growth-hormone-releasing hormone, which is the shortest fragment that keeps full biological activity. Its weakness is its speed: it is broken down by enzymes within roughly 10 to 20 minutes, so it gives a brief, natural-shaped pulse of growth hormone and then clears. Tesamorelin is a longer GHRH(1-44) analog with a chemical modification (a trans-3-hexenoyl group) bolted onto one end specifically to resist the enzyme that would otherwise chew it up. That stabilization gives it a longer effective half-life and a stronger, more sustained push on the GH-IGF-1 axis, which is the leading explanation for why it produces a measurable fat-loss outcome where sermorelin's gentler pulse has not been shown to. Because tesamorelin drives IGF-1 higher, it also carries more of the theoretical risks that come with elevated IGF-1, which is part of why it is a monitored prescription drug and not a casual supplement. This mechanistic difference, not marketing, is why the two are not interchangeable doses of "a GH peptide."
Tolerability: both mild, sermorelin a touch gentler
The one-sentence answer: both are generally well tolerated and far milder than the GLP-1 weight-loss drugs, with sermorelin reporting slightly fewer local reactions in our community data. Neither is a rough ride, so tolerability rarely decides this on its own.
In our community reports the most common complaints are local and minor: injection-site reactions (sermorelin 15% vs tesamorelin 24%), numbness or tingling (6% vs 10%), headache (about 8% for both), and nausea (about 5% for both). These are self-reported community frequencies, not trial incidence and not proof of cause, but the pattern is consistent: tesamorelin, being the stronger and longer-acting molecule, tends to produce a few more local and neuro-type complaints, while the systemic effects are mild and similar for both. The numbness-and-tingling signal on tesamorelin is worth flagging because it can reflect fluid-balance shifts that come with a stronger GH push.
The one tolerability point that actually matters for tesamorelin is metabolic: because it pushes IGF-1 harder, prescribers monitor blood sugar and IGF-1 levels, since a stronger GH signal can nudge glucose handling. That is a managed risk, not a dealbreaker, but it is the kind of thing that belongs under a clinician's eye. For the complete tolerability breakdown and red-flag list, read sermorelin side effects and tesamorelin side effects. This page does not duplicate them.
Cost: the place sermorelin clearly wins
The one-sentence answer: sermorelin is dramatically cheaper, roughly a tenth of tesamorelin's per-dose cost in our community data, and over a year that gap is large enough to decide the question for anyone without a specific tesamorelin-shaped goal. Cost is the single biggest reason people stay on, or drift back to, sermorelin.
In ProtocolPlus cost figures, sermorelin runs about a median $1.60 per dose (vials roughly $25 to $55, around 25 doses each) versus about $17 per dose for tesamorelin (vials roughly $50 to $120, around 5 doses each). The gap is even starker at brand level: Egrifta has historically listed around $28,000 to $33,000 per year, while compounded sermorelin runs a few hundred dollars a month. That order-of-magnitude difference is exactly why the community splits by goal: tesamorelin's price is only justified when you specifically want its trial-proven visceral-fat effect, and sermorelin is the sensible default for everything more general. We do not quote a single brand price as a quote because compounded and brand pricing both vary widely by pharmacy and program; treat the per-dose community figures as a directional signal, not a quote.
Speed and the first few weeks
The one-sentence answer: neither is an overnight change, and both work on the slow timescale of the GH-IGF-1 axis, so "which is faster" is mostly the wrong question. Subtle effects like sleep quality can show up within the first couple of weeks on either, but body-composition change is a months-long process, and tesamorelin's trial result was measured at 26 weeks for a reason.
The practical reality is that both build effect gradually as nightly or daily dosing accumulates, and the honest expectation for either is steady, unglamorous change over months rather than weeks. Tesamorelin's larger eventual effect comes from its stronger, more sustained push on the axis, not from acting faster early on. People who switch for "speed" are usually really switching for a bigger ceiling on a specific outcome, which is a different thing, and in this pairing that outcome is visceral fat.
The editorial scorecard (the "why," not the verdict)
The fit-score radar below rates each peptide 1 to 5 on six dimensions. With equal weighting they land close (sermorelin 60, tesamorelin 57): tesamorelin leads on evidence and effectiveness, sermorelin leads on cost and tolerability, and they tie on accessibility and speed. That near-tie is the honest summary, and it underlines the theme of this whole page. The community usage data above, not this radar, is the headline signal, and your own goal decides which dimension matters most.
Choose sermorelin if... / Choose tesamorelin if...
The decision rarely needs a coin flip, because it follows your goal. These two cards cover the great majority of cases.
Choose sermorelin if:
- You want general, gentle growth-hormone-axis support rather than one targeted outcome.
- Cost matters. At roughly $1.60 vs $17 per dose in our data, sermorelin is dramatically cheaper.
- You prefer the better-tolerated option (fewer injection-site reactions in our reports).
- You are comfortable with a compounded peptide and with the fact that anti-aging use is off-label and unvalidated.
Choose tesamorelin if:
- Visceral (deep belly) fat is the specific goal. It is the only one with a randomized trial behind that result.
- You want the molecule with an actual FDA approval and a real evidence base.
- You can absorb the much higher cost for the stronger data.
- You have HIV-associated lipodystrophy (the on-label use) and a prescriber to monitor IGF-1 and glucose.
The honest verdict
There is no single winner here, and any page that crowns one is selling you something. Tesamorelin is the better-evidenced, FDA-approved, trial-proven choice for one specific job: shrinking visceral fat. Sermorelin is the cheaper, gentler, general-purpose choice for broad growth-hormone-axis support, and its low price is a real advantage that a slim majority of our community values enough to stay on it. The community confirms the framing rather than picking a champion: the split is near-even, almost nobody runs both, and the switch traffic is a wash. If you are choosing today, let your goal decide. Want a result with a trial behind it, specifically for belly fat, and can pay for it? Tesamorelin. Want affordable, well-tolerated general support and accept that the anti-aging case is unproven? Sermorelin. Either way, both sit inside a clinician-supervised plan, not a decision to make from a comparison page alone.
To make it concrete, here is how the decision usually lands by situation:
- Visceral / belly fat is the explicit goal: tesamorelin (the only one with trial data).
- Tight budget, general support: sermorelin (about a tenth of the per-dose cost).
- Want an FDA-approved molecule with real evidence: tesamorelin.
- Most sensitive to injection-site reactions: sermorelin runs gentler in our reports.
- HIV-associated lipodystrophy: tesamorelin (Egrifta) is the one approved for it.
- Just exploring the GHRH class affordably: sermorelin is the usual entry point.
For how each stacks against the other popular GH-axis peptides, see sermorelin vs ipamorelin. For the full molecule deep-dives, see the sermorelin and tesamorelin guides.
Frequently Asked Questions
Sources
- Falutz J, Allas S, Blot K, et al. "Metabolic Effects of a Growth Hormone-Releasing Factor in Patients with HIV" (tesamorelin Phase 3). New England Journal of Medicine, 2007;357(23):2359-2370. Retrieved 2026-06-18. https://www.nejm.org/doi/full/10.1056/NEJMoa072375
- U.S. Food & Drug Administration. "EGRIFTA (tesamorelin for injection) Prescribing Information" (FDA approval, 2010, HIV-associated lipodystrophy). Retrieved 2026-06-18. https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022505s000lbl.pdf
- U.S. Food & Drug Administration / Federal Register. "Determination That GEREF (Sermorelin Acetate) Injection Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness." 2013. Retrieved 2026-06-18. https://www.federalregister.gov/documents/2013/03/04/2013-04827
- HIV i-Base. "FDA approves tesamorelin (Egrifta) for reduction of central fat accumulation." 2010. Retrieved 2026-06-18. https://i-base.info/htb/14188
- CADTH / NCBI Bookshelf. "Pharmacoeconomic Review Report: Tesamorelin (Egrifta) - Cost Comparison." Retrieved 2026-06-18. https://www.ncbi.nlm.nih.gov/books/NBK538950/
- ProtocolPlus. "Community head-to-head data: sermorelin vs tesamorelin" (head-to-head/sermorelin__tesamorelin.json). First-party app data, 2026. n ~ 1,072 users tracking one of the two. Usage and switching signal, not a clinical efficacy verdict.